53658-91-6

Upstream product

• 23074-42-2 1-adamantanecarbonitrile 

Downstream Products

• 1443017-26-2 3-((3r,5r,7r)-adamantan-1-yl)-5-phenyl-1,2,4-oxadiazole 
• 1443017-27-3 3-(adamantan-1-yl)-5-(4-fluorophenyl)-1,2,4-oxadiazole 
• 1443017-28-4 3-(adamantan-1-yl)-5-(4-methylphenyl)-1,2,4-oxadiazole 
• 1430424-06-8 C₂₅H₃₀ClN₃O₂ 

Relevant academic research and scientific papers

Adamantylchlorocarbene: Characterization and rearrangement to chlorohomoadamant-3-ene

Adamantylchlorocarbene and its ring-expanded product, chlorohomoadamant- 3-ene, have been characterized by matrix isolation spectroscopy combined with DFT calculations.

Design, synthesis and SAR of piperidyl-oxadiazoles as 11β- hydroxysteroid dehydrogenase 1 inhibitors

The potential roles of 11β-HSD1 inhibitors in metabolic syndrome, T2D and obesity were well established and currently several classes of 11β-HSD1 inhibitors have been developed as promising agents against metabolic diseases. To find potent compounds with good pharmacokinetics, we used the bioisosterism approach, and designed the compound 2 and 3 bearing an 1,2,4-oxadiazole ring to replace the amide group in compound 1. Guided by docking study, we then transformed compound 3 into a potent lead compound 4a by changing sulfonamide group to amide. To elaborate this series of piperidyl-oxadiazole derivatives as human 11β-HSD1 inhibitors, we explored the structure-activity relationship of several parts of the lead compound. Based on their potency toward human 11β-HSD1 two compounds 4h and 4q were advanced to pharmacokinetic study. It was found that 4h and 4q are potent and selective human 11β-HSD1 inhibitors with better pharmacokinetic properties than those of the original piperidine-3-carboxamide compound 1, and suitable for further in vivo preclinical study in primate model.

ADAMANTANE ANALOGS

Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being capable of interaction with the M2 protein.